A study has revealed that a laboratory test analyzing brain and spinal cord fluid for a protein called alpha-synuclein can accurately detect Parkinson’s disease. The study involved over 1,100 people and the test was able to identify abnormal protein accumulations in 88% of all participants with Parkinson’s disease. The results may pave the way for drug development and could help doctors make a specific diagnosis when used in conjunction with other evaluations.

Parkinson’s disease is a progressive disorder that affects movement, often leading to tremors and difficulty with coordination. While it is usually diagnosed in people over 60, researchers have been working to identify ways to spot the disease earlier. A recent study developed a new test that may be able to detect early Parkinson’s disease before symptoms become severe. In this article, we will analyze the findings of this breakthrough study and the potential impact it could have on Parkinson’s diagnosis and treatment.


A new study has discovered that a laboratory test analyzing brain and spinal cord fluid for clumps of alpha-synuclein protein can accurately detect Parkinson’s disease. The test was performed on over 1,100 participants and was published in the Lancet Neurology in May 2023. The study found that the lab test could identify abnormal protein accumulations in 88% of all participants with Parkinson’s disease. Alpha-synuclein is a hallmark of the neurological disorder that affects nearly one million people in the United States.

The test, SYNTap, can detect the misfolded and clumped proteins that form aggregates or “seeds” believed to cause the disease. The new biomarker test is seen as a breakthrough for Parkinson’s research and is part of the Michael J. Fox Foundation for Parkinson’s Research’s Parkinson’s Progression Markers Initiative (PPMI). The research included more than 500 people with Parkinson’s disease, almost 400 with sporadic disease, more than 100 with LRRK2 gene mutations, and close to 50 with GBA gene mutations. The study also included more than 300 participants with gene mutations but no disease symptoms and more than 50 with Parkinson’s symptoms but no signs of dopamine deficiencies on brain scans.

Parkinson’s disease is characterized by the loss of dopamine in the brain, leading to movement problems such as tremors, rigidity, and slowed movement. The new test is seen as a way to diagnose Parkinson’s earlier, allowing patients to make lifestyle changes early on, when their brain is healthier and more responsive to intervention. The Parkinson Disease Association advises regular exercise and a healthy diet to maintain mobility and promote general well-being for Parkinson’s patients.

While the test alone cannot provide a definitive diagnosis, the study authors noted that the test could help doctors make a specific diagnosis when used in conjunction with other evaluations. The new biomarker test may also pave the way for drug development, as drug development for neurodegenerative diseases has been challenging. The study authors suggest that the best option is to identify subjects very early on and test drugs that can slow down or stop the disease at that early stage. Further research is required to identify whether prodromal people are positive in tests, and researchers are also exploring other types of testing that can detect alpha-synuclein seeds via nasal swabs, skin biopsy, and blood.


In conclusion, this breakthrough test for detecting early Parkinson’s disease provides hope and potential for earlier intervention and better management of the disease. While more research and trials are needed, this exciting discovery is a step forward in understanding and treating Parkinson’s disease. It also highlights the importance of early detection for better outcomes in neurological diseases. With continued advancements in medical technology and research, we may eventually find a cure for Parkinson’s disease, but until then, early detection and management can help improve the quality of life for those living with the disease.